Every material Form 8-K Gilead Sciences has filed with the SEC since November 19, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Gilead Sciences announced its third quarter 2026 financial results, reporting a 13% increase in total product sales to $8.3 billion driven by growth in HIV and oncology products. The company also raised its full-year 2026 base business revenue guidance for the year, bringing total increases to $1.6 billion since the start of the year.
Total third quarter 2026 product sales increased 13% year-over-year to $8.3 billion.
GAAP diluted earnings per share was $1.94 for the third quarter of 2026 compared to $2.43 in the prior year period.
Full-year 2026 product sales guidance was raised to a range of $31.0 billion to $31.3 billion.
As of September 30, 2026, cash, cash equivalents and marketable debt securities totaled $6.4 billion.
Gilead reported second quarter 2026 total revenues of $7.8 billion, up 10% from a year earlier, and raised its full-year 2026 product sales guidance. The company posted a GAAP diluted loss of $(8.45) per share, driven by $11.2 billion of acquired in-process R&D expenses tied to recent acquisitions, and its full-year GAAP loss per share guidance was widened.
Total revenues rose 10% to $7.8 billion; HIV product sales rose 12% to $5.7 billion.
GAAP diluted loss per share was $(8.45), compared with diluted earnings of $1.56 a year earlier, mainly due to $(9.08) per share of acquired IPR&D and tax expenses.
Full-year 2026 GAAP diluted loss per share guidance is $(3.75) to $(3.40), down from the prior $(3.25) to $(2.85); product sales guidance is $30.1 billion to $30.4 billion, up from $30.0 billion to $30.4 billion.
Cash, cash equivalents and marketable debt securities were $3.2 billion at June 30, 2026, compared with $10.6 billion at December 31, 2025.
Gilead Sciences issued $3.0 billion of senior notes in four tranches, under an underwriting agreement dated May 14, 2026, and a supplemental indenture dated May 20, 2026. The company said it will use the net proceeds for general corporate purposes, which may include acquisitions, investments and other strategic transactions.
Four series: $500 million 4.250% notes due 2028, $1.0 billion 4.400% notes due 2029, $1.0 billion 4.600% notes due 2031, and $500 million 4.900% notes due 2034
Notes were sold in a public offering under shelf registration Form S-3 (File No. 333-273745); underwriters include Barclays Capital, BofA Securities and Citigroup Global Markets
Indenture restricts secured debt, sale and leaseback transactions, and mergers or asset transfers, and requires an offer to repurchase notes upon certain change of control events
Gilead reported first-quarter 2026 total revenue of $7.0 billion, up 4% from a year earlier, and GAAP diluted EPS of $1.61 versus $1.04. The company cut its full-year 2026 GAAP diluted EPS guidance to a loss of $(3.25) to $(2.85) from $6.75 to $7.15, citing anticipated acquired IPR&D charges of $11.5 billion and financing costs tied to the Arcellx, Ouro and Tubulis acquisitions, while raising its product sales guidance.
Q1 2026 total revenues rose 4% to $7.0 billion; GAAP diluted EPS was $1.61 versus $1.04 and non-GAAP diluted EPS was $2.03 versus $1.81.
Full-year 2026 GAAP diluted EPS guidance is $(3.25) to $(2.85), down from $6.75 to $7.15; non-GAAP guidance is $(1.05) to $(0.65), down from $8.45 to $8.85.
Full-year 2026 product sales guidance was raised to $30.0 billion to $30.4 billion from $29.6 billion to $30.0 billion.
Cash and marketable debt securities fell to $8.6 billion at March 31, 2026, from $10.6 billion at December 31, 2025; the Board declared a $0.82 quarterly dividend payable June 29, 2026.
Gilead Sciences completed its acquisition of Arcellx, Inc. on April 28, 2026, paying $115 per share in cash plus one contingent value right of $5 per share, for a total implied equity value of about $7.8 billion. Gilead said the deal will reduce its GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 to $5.67, so shareholders face a large near-term earnings charge tied to the anito-cel program's future success.
Acquisition completed April 28, 2026, after tender offer expired April 27 with about 77.2% of Arcellx shares outstanding tendered or already owned by Gilead
Total funds used were approximately $7.1 billion; implied equity value at closing was about $7.8 billion
Gilead expects 2026 diluted EPS to fall by approximately $5.57 to $5.67; excluding acquired in-process R&D, it expects modest dilution in 2026 and 2027 and accretion from 2028, subject to FDA approval of anito-cel
CVR pays $5 per share if cumulative global net sales of anito-cel reach at least $6.0 billion from launch through 2029
Gilead Sciences agreed on February 22, 2026 to acquire Arcellx through a tender offer followed by a second-step merger, offering $115 per share in cash plus one contingent value right worth up to $5 per share if anito-cel cumulative sales reach $6.0 billion by year-end 2029. The company said the deal implies an equity value of $7.8 billion and is expected to close in the second quarter of 2026, which would add a large, pre-approval acquisition to Gilead's balance sheet and affect shareholders through its cost and future earnings contribution.
Offer price of $115 per share in cash plus one CVR paying $5 per share on cumulative anito-cel sales of at least $6.0 billion through 2029
Implied equity value of $7.8 billion; Gilead already owns about 11.5 percent of Arcellx's common stock
Expected close in the second quarter of 2026, subject to tender, regulatory and other conditions
Arcellx would pay Gilead a $260 million termination fee in specified circumstances; the deal is expected to be accretive to earnings per share in 2028 and thereafter, after FDA approval of anito-cel
Gilead reported fourth quarter and full year 2025 results on February 10, 2026. Fourth quarter revenue rose 5% to $7.9 billion and GAAP diluted EPS rose to $1.74 from $1.42, while non-GAAP diluted EPS fell to $1.86 from $1.90. The company also issued full year 2026 guidance, with diluted EPS of $6.75 to $7.15 and non-GAAP diluted EPS of $8.45 to $8.85.
Q4 2025 total revenues rose 5% to $7.9 billion; Q4 diluted EPS was $1.74 versus $1.42 a year earlier
Q4 2025 non-GAAP diluted EPS was $1.86 versus $1.90, reflecting higher acquired IPR&D expenses of $539 million
Full year 2025 revenues rose 2% to $29.4 billion; diluted EPS was $6.78 versus $0.38 in 2024
2026 guidance: product sales of $29.6 billion to $30.0 billion; the board declared a $0.82 quarterly dividend payable March 30, 2026
Gilead Sciences disclosed that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel effective December 5, 2025, with her employment ending later in the month. The filing does not give a reason for the departure or name a successor, so shareholders have no information yet on how the change will affect the company's legal and corporate affairs functions.
Deborah H. Telman leaves the role of Executive Vice President, Corporate Affairs and General Counsel effective December 5, 2025.
Her employment with the company will terminate later in November 2025, according to the filing.
The filing does not name a successor or state the reason for the departure.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Gilead Sciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →